Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06447025 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
A Phase 2 study, sponsored by Larimar Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT06447025: Recruiting Phase 2 study, sponsored by Larimar Therapeutics.
NCT06447025 is a Phase 2 study that is actively recruiting participants, run by Larimar Therapeutics. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06447025, a Phase 2 study, is actively recruiting participants, sponsored by Larimar Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and adults with FRDA who have not participated in a prior clinical study of CTI-1601.
Primary Outcome
Number of subjects
Interventions
- DRUG CTI-1601
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2024-01-25 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT06447025 shows while recruiting
NCT06447025 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 0 conditions, and to 1 intervention - of which CTI-1601 is the first listed.
NCT06447025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06447025 about?
NCT06447025 is a clinical study titled "An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia". An open label study designed to evaluate the safety, PK, PD, and clinical effects of long-term daily administration of CTI-1601 enrolling adolescent and adult patients with FRDA who have participated in a prior clinical study of CTI-1601 as well as children (age 2 years and older), adolescents and a...
What is the current status of trial NCT06447025?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2024-01-25. Estimated completion is 2027-01.
What interventions are being tested in trial NCT06447025?
The interventions under investigation include: CTI-1601 (DRUG).
Who is sponsoring clinical trial NCT06447025?
This trial is sponsored by Larimar Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06447025's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI